After-Hours Stock Movers 11/01: (PTN) (AVXS) (EA) Higher; (ADPT) (ZAGG) (DXCM) Lower (more...)

November 1, 2016 6:25 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's After-Hours Movers

Adeptus Health (NYSE: ADPT) 48% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.

Palatin Technologies, Inc. (NYSE: PTN) 46.9% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met the pre-specified co-primary efficacy endpoints in both Phase 3 clinical trials.

AGG, Inc. (NASDAQ: ZAGG) 19.2% LOWER; reported Q3 EPS of $0.29, $0.15 better than the analyst estimate of $0.14. Revenue for the quarter came in at $124.7 million versus the consensus estimate of $121.76 million.

DexCom (NASDAQ: DXCM) 17.8% LOWER; reported Q3 EPS of ($0.22), $0.09 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $148.6 million versus the consensus estimate of $146.26 million.

AveXis, Inc. (NASDAQ: AVXS) 15.6% HIGHER; announced that the planned pivotal study of AVXS-101 in spinal muscular atrophy (SMA) Type 1 will reflect a single-arm design, using natural history of the disease as a comparator, and enroll approximately 20 patients. This update is based on the receipt of the minutes following the Type B meeting with the U.S. Food and Drug Administration (FDA) held on September 30, 2016.

Myriad Genetics (NASDAQ: MYGN) 8.7% LOWER; reported Q1 EPS of $0.23, $0.02 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $177.5 million versus the consensus estimate of $172.85 million. GUIDANCE: Myriad Genetics sees Q2 2017 EPS of $0.23-$0.25, versus the consensus of $0.27. Myriad Genetics sees Q2 2017 revenue of $188-190 million, versus the consensus of $193.37 million. Myriad Genetics sees FY2017 EPS of $1.00-$1.10, versus the consensus of $1.06. Myriad Genetics sees FY2017 revenue of $740-760 million, versus the consensus of $748.23 million.

DHT Holdings (NYSE: DHT) 8.3% LOWER; reported Q3 EPS of ($0.81), $0.85 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $50.3 million versus the consensus estimate of $56.73 million. Cuts dividend.

U.S. Steel (NYSE: X) 7.6% LOWER; reported Q3 EPS of $0.32, $0.48 worse than the analyst estimate of $0.80. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.82 billion.

Electronic Arts (NASDAQ: EA) 6.6% HIGHER; reported Q2 EPS of ($0.13), may not compare to the analyst estimate of $0.43. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.09 billion. GUIDANCE: Electronic Arts sees FY2017 EPS of $2.69, may not compare to consensus of $3.64. Electronic Arts sees FY2017 revenue of $4.775 billion, versus the consensus of $4.95 billion.

Cerner (NASDAQ: CERN) 6% LOWER; reported Q3 EPS of $0.59, $0.01 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $1.19 billion versus the consensus estimate of $1.24 billion. GUIDANCE: Cerner sees Q4 2016 EPS of $0.60-$0.62, versus the consensus of $0.65. Cerner sees Q4 2016 revenue of $1.225-1.30 billion, versus the consensus of $1.32 billion. Cerner sees FY2017 EPS of $2.50-$2.70, versus the consensus of $2.69. Cerner sees FY2017 revenue of $5.2-5.45 billion, versus the consensus of $5.44 billion.

Oclaro (NASDAQ: OCLR) 5.7% HIGHER; reported Q1 EPS of $0.14, $0.04 better than the analyst estimate of $0.10. Revenue for the quarter came in at $135.5 million versus the consensus estimate of $131.65 million.

Inphi Corp. (NYSE: IPHI) 5.6% HIGHER; reported Q3 EPS of $0.46, $0.08 better than the analyst estimate of $0.38. Revenue for the quarter came in at $70.7 million versus the consensus estimate of $67.89 million.

Zendesk (NYSE: ZEN) 5.6% LOWER; reported Q3 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $80.7 million versus the consensus estimate of $79.45 million. GUIDANCE: Zendesk sees FY2016 revenue of $309-311 million, versus the consensus of $309.8 million.

Paycom Software (NYSE: PAYC) 5.2% LOWER; reported Q3 EPS of $0.15, $0.03 better than the analyst estimate of $0.12. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $76.71 million. GUIDANCE: Paycom Software sees Q4 2016 revenue of $85-87 million, versus the consensus of $85.94 million.

Big 5 Sporting Goods (NASDAQ: BGFV) 5% HIGHER; reported Q3 EPS of $0.38, $0.08 better than the analyst estimate of $0.30. Revenue for the quarter came in at $279 million versus the consensus estimate of $274.64 million.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) 4.8% LOWER; announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In this Phase 2 study patients treated with IONIS-FXIRx achieved statistically significant, dose-dependent reductions in Factor XI activity. There were no clinically meaningful reductions in platelet levels and no treatment-related major or clinically relevant non-major bleeding events.

Square (NYSE: SQ) 4.1% HIGHER; reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $439 million versus the consensus estimate of $430.09 million.

Lantheus Holdings (NASDAQ: LNTH) 3.9% HIGHER; reported Q3 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $73.1 million versus the consensus estimate of $69.72 million. GUIDANCE: Lantheus Holdings sees FY2016 revenue of $296-299 million, versus the consensus of $294 million.

Valeant Pharmaceuticals (NYSE: VRX) 3% LOWER; gives back some of intra-day following reports it is selling Salix for $10B,

Etsy (NASDAQ: ETSY) 1.7% HIGHER; reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $87.56 million versus the consensus estimate of $86.79 million.

tronc (NASDAQ: TRNC) 0.7% HIGHER; reported Q3 adj EPS of $0.22, versus ($0.07) reported last year. Revenue for the quarter came in at $378 million, versus $406 million reported last year.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

After-Hours Movers, S1

Add Your Comment